

Lorenzo Beretta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5520491/publications.pdf>

Version: 2024-02-01

110
papers

4,947
citations

101543

36
h-index

106344

65
g-index

114
all docs

114
docs citations

114
times ranked

6372
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2 β . <i>Rheumatology</i> , 2022, 61, 2682-2693.	1.9	6
2	The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. <i>Vaccines</i> , 2022, 10, 663.	4.4	10
3	Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort. <i>Journal of Clinical Medicine</i> , 2022, 11, 3587.	2.4	7
4	Genomic Risk Score impact on susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 118-127.	0.9	20
5	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	5.6	81
6	Cardiovascular Autonomic Control, Sleep and Health Related Quality of Life in Systemic Sclerosis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2276.	2.6	8
7	Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis. <i>Rheumatology</i> , 2021, 61, 154-162.	1.9	9
8	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.9	24
9	Expression Quantitative Trait Locus Analysis in Systemic Sclerosis Identifies New Candidate Genes Associated With Multiple Aspects of Disease Pathology. <i>Arthritis and Rheumatology</i> , 2021, 73, 1288-1300.	5.6	9
10	A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. <i>Nature Communications</i> , 2021, 12, 3523.	12.8	67
11	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021, 231, 108845.	3.2	14
12	Implication of miR-126 and miR-139-5p in Plasmacytoid Dendritic Cell Dysregulation in Systemic Sclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 491.	2.4	20
13	Integrative epigenomics in Sjögren's syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. <i>Scientific Reports</i> , 2021, 11, 23292.	3.3	16
14	Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögren's syndrome. <i>European Journal of Immunology</i> , 2020, 50, 119-129.	2.9	39
15	Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1581-1586.	1.9	22
16	Discovering new metabolite alterations in primary sjögren's syndrome in urinary and plasma samples using an HPLC-ESI-QTOF-MS methodology. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 179, 112999.	2.8	14
17	Systemic lupus erythematosus and COVID-19: what we know so far. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218601.	0.9	12
18	Angiotensin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9544.	4.1	8

#	ARTICLE	IF	CITATIONS
19	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. <i>Autoimmunity Reviews</i> , 2020, 19, 102583.	5.8	25
20	Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1218-1226.	0.9	26
21	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1150-1157.	3.4	52
22	CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis. <i>Journal of Autoimmunity</i> , 2020, 111, 102444.	6.5	28
23	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	3.8	28
24	IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. <i>Scientific Reports</i> , 2019, 9, 14834.	3.3	16
25	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	12.8	100
26	Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases. <i>Journal of Clinical Medicine</i> , 2019, 8, 1291.	2.4	37
27	Cardiac autonomic modulation at rest and during orthostatic stress among different systemic sclerosis subsets. <i>European Journal of Internal Medicine</i> , 2019, 66, 75-80.	2.2	21
28	Ilprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366.	3.6	23
29	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	3.8	19
30	Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 529-538.	0.9	40
31	The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 100.	4.8	58
32	Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000783.	3.8	30
33	FRI0607â€¦IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		0
34	Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 162, 82-90.	2.8	29
35	Abatacept to treat chronic intestinal pseudo-obstruction in five systemic sclerosis patients with a description of the index case. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, NP5-NP9.	1.7	3
36	Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2018, 89, 162-170.	6.5	65

#	ARTICLE	IF	CITATIONS
37	Moving towards a molecular taxonomy of autoimmune rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2018, 14, 75-93.	8.0	80
38	FOXP3 , ICOS and ICOSL gene polymorphisms in systemic sclerosis: FOXP3 rs2294020 is associated with disease progression in a female Italian population. <i>Immunobiology</i> , 2018, 223, 112-117.	1.9	8
39	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	2.5	3
40	Microbial and metabolic multi-omic correlations in systemic sclerosis patients. <i>Annals of the New York Academy of Sciences</i> , 2018, 1421, 97-109.	3.8	50
41	Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 6.5 312-331.		15
42	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1337-1338.	5.6	9
43	Association of MicroRNA-18 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1891-1902.	5.6	67
44	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
45	Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum. <i>Arthritis and Rheumatology</i> , 2017, 69, 2359-2369.	5.6	33
46	Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. <i>Arthritis Research and Therapy</i> , 2017, 19, 145.	3.5	39
47	An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 1453-1457.	2.0	25
48	Nearest neighbor imputation algorithms: a critical evaluation. <i>BMC Medical Informatics and Decision Making</i> , 2016, 16, 74.	3.0	328
49	The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis. <i>Clinical Immunology</i> , 2016, 173, 76-80.	3.2	23
50	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	5.6	46
51	Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients. <i>Rheumatology</i> , 2016, 55, 1112-1116.	1.9	33
52	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.9	41
53	The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1567-1573.	0.9	126
54	Regional Implantation of Autologous Adipose Tissue-Derived Cells Induces a Prompt Healing of Long-Lasting Indolent Digital Ulcers in Patients with Systemic Sclerosis. <i>Cell Transplantation</i> , 2015, 24, 2297-2305.	2.5	80

#	ARTICLE	IF	CITATIONS
55	Reply to J. Magalon et al.. Cell Transplantation, 2015, 24, 2669-2670.	2.5	3
56	Validation of a Novel Radiographic Scoring System for Calcinosis Affecting the Hands of Patients With Systemic Sclerosis. Arthritis Care and Research, 2015, 67, 425-430.	3.4	44
57	Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosis. Rheumatology, 2015, 54, 707-711.	1.9	21
58	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
59	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.8	4
60	Identification of <i>IL12RB1</i> as a Novel Systemic Sclerosis Susceptibility Locus. Arthritis and Rheumatology, 2014, 66, 3521-3523.	5.6	29
61	Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis. New England Journal of Medicine, 2014, 370, 433-443.	27.0	365
62	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Research and Therapy, 2014, 16, R6.	3.5	37
63	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	6.2	182
64	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
65	Extension of the survival dimensionality reduction algorithm to detect epistasis in competing risks models (SDR-CR). Journal of Biomedical Informatics, 2013, 46, 174-180.	4.3	0
66	Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients. European Journal of Internal Medicine, 2013, 24, 671-676.	2.2	25
67	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.	0.9	56
68	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.9	30
69	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human Molecular Genetics, 2013, 22, 4021-4029.	2.9	104
70	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS ONE, 2013, 8, e54419.	2.5	38
71	A GWAS follow-up study reveals the association of the <i>IL12RB2</i> gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 2012, 21, 926-933.	2.9	74
72	Analysis of Class II human leucocyte antigens in Italian and Spanish systemic sclerosis. Rheumatology, 2012, 51, 52-59.	1.9	46

#	ARTICLE	IF	CITATIONS
73	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. <i>Human Molecular Genetics</i> , 2012, 21, 2825-2835.	2.9	98
74	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. <i>Journal of Rheumatology</i> , 2012, 39, 112-118.	2.0	8
75	KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. <i>Arthritis Research and Therapy</i> , 2012, 14, R273.	3.5	10
76	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R154.	3.5	11
77	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	3.5	32
78	Implementing ReliefF filters to extract meaningful features from genetic lifetime datasets. <i>Journal of Biomedical Informatics</i> , 2011, 44, 361-369.	4.3	25
79	Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension. <i>European Journal of Pharmacology</i> , 2011, 667, 287-291.	3.5	12
80	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. <i>Arthritis and Rheumatism</i> , 2011, 63, 2790-2796.	6.7	53
81	Modelling epistasis in genetic disease using Petri nets, evolutionary computation and frequent itemset mining. <i>Expert Systems With Applications</i> , 2011, 38, 4006-4013.	7.6	4
82	A replication study confirms the association of <i>TNFSF4 (OX4L)</i> polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.9	63
83	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. <i>Rheumatology</i> , 2011, 50, 1976-1981.	1.9	27
84	Models for prediction of death in systemic sclerosis: current perspectives and future directions. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 391-393.	3.0	3
85	The Functional Polymorphism 844 A>G in FcÎ±RI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility. <i>Journal of Rheumatology</i> , 2011, 38, 446-449.	2.0	4
86	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2050-2052.	0.9	15
87	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201
88	Survival dimensionality reduction (SDR): development and clinical application of an innovative approach to detect epistasis in presence of right-censored data. <i>BMC Bioinformatics</i> , 2010, 11, 416.	2.6	12
89	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	21.4	351
90	Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies. <i>Journal of Rheumatology</i> , 2010, 37, 2290-2298.	2.0	259

#	ARTICLE	IF	CITATIONS
91	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	2.0	9
92	A 3-factor epistatic model predicts digital ulcers in Italian scleroderma patients. <i>European Journal of Internal Medicine</i> , 2010, 21, 347-353.	2.2	7
93	Evolving Concurrent Petri Net Models of Epistasis. <i>Lecture Notes in Computer Science</i> , 2010, , 166-175.	1.3	1
94	Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S18-27.	0.8	45
95	Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability. <i>Rheumatology</i> , 2009, 48, 1619-1620.	1.9	3
96	5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population – authors' response. <i>Arthritis Research and Therapy</i> , 2009, 11, 404.	3.5	1
97	Ability of epistatic interactions of cytokine single nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , 2008, 59, 974-983.	6.7	35
98	A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. <i>Arthritis Research and Therapy</i> , 2008, 10, R103.	3.5	29
99	Interleukin-1 gene complex single nucleotide polymorphisms in systemic sclerosis: A further step ahead. <i>Human Immunology</i> , 2008, 69, 187-192.	2.4	12
100	Effects of aminaftone 75 mg TID on soluble adhesion molecules: A 12-week, randomized, open-label pilot study in patients with systemic sclerosis. <i>Clinical Therapeutics</i> , 2008, 30, 924-929.	2.5	15
101	Aminaftone, a Derivative of 4-Aminobenzoic Acid, Downregulates Endothelin-1 Production in ECV304 Cells. <i>Drugs in R and D</i> , 2008, 9, 251-257.	2.2	11
102	HLA-B35 Influences the Apoptosis Rate in Human Peripheral Blood Mononucleated Cells and HLA-Transfected Cells. <i>Human Immunology</i> , 2007, 68, 181-191.	2.4	5
103	Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology. <i>Human Immunology</i> , 2007, 68, 603-609.	2.4	38
104	No evidence for a role of the proximal IL6 G/C –174 single nucleotide polymorphism in Italian patients with systemic sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 896-898.	3.6	4
105	T-889C IL-1 promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. <i>Clinical Rheumatology</i> , 2007, 26, 88-91.	2.2	17
106	Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. <i>Clinical Rheumatology</i> , 2006, 26, 168-172.	2.2	37
107	Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. <i>Rheumatology</i> , 2006, 46, 296-301.	1.9	57
108	Systemic sclerosis following oral contraception. <i>Clinical Rheumatology</i> , 2005, 24, 316-317.	2.2	5

#	ARTICLE	IF	CITATIONS
109	Postmenopause is the Main Risk Factor for Developing Isolated Pulmonary Hypertension in Systemic Sclerosis. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 238-246.	3.8	93
110	The Systolic Pulmonary Arterial Pressure Liases Impaired Cardiac Autonomic Control to Pro-inflammatory Status in Systemic Sclerosis Patients. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2